SCHEMBL4808985

SCHEMBL4808985

COc1cc(-c2ccc(Br)cc2)ccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.53
CSNK2A2 P19784 2/20 0.52
CSNK2B P67870 2/20 0.52
CSNK2A1 P68400 2/20 0.52
APP P05067 2/20 0.51
POLB P06746 1/20 0.51
CXCL12 P48061 1/20 0.50
ALOX5 P09917 1/20 0.49
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
GAA P10253 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386820 0.90 MAOB (0.64) MAOBPOLBCXCL12ALOX5PTGS1
SCHEMBL3693339 0.88 MAOB (0.67) MAOBPOLBCXCL12ALOX5PTGS1
SCHEMBL3813200 0.84 MAOB (0.69) MAOBCSNK2A2CSNK2BCSNK2A1POLB
SCHEMBL18121551 0.84 MAOB (0.57) MAOBPOLBALOX5PTGS1PTGS2
SCHEMBL9622952 0.84 MAOB (0.69) MAOBCSNK2A2CSNK2BCSNK2A1POLB
SCHEMBL29744489 0.84 MAOB (0.61) MAOBCSNK2A2CSNK2BCSNK2A1APP
SCHEMBL74689 0.84 MAOB (0.61) MAOBCSNK2A2CSNK2BCSNK2A1APP
SCHEMBL30957832 0.82 POLB (0.62) MAOBPOLBALOX5GAAMEN1
SCHEMBL8338706 0.82 FYN (0.61) MAOBCSNK2A2CSNK2BCSNK2A1POLB
SCHEMBL2524920 0.82 POLB (0.62) MAOBPOLBALOX5GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 MAOB 3311/4885CSNK2A2 164/4885CSNK2B 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.